Literature DB >> 18622696

Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions.

Osvaldo Pontiggia1, Vanina Rodriguez, Victoria Fabris, Diego Raffo, Viviana Bumaschny, Gabriel Fiszman, Elisa Bal de Kier Joffé, Marina Simian.   

Abstract

Currently, to our knowledge, there are no continuous cell lines derived from estrogen dependent, tamoxifen sensitive spontaneous mouse mammary carcinomas. We describe here the establishment and characterization of a cell line derived from the M05 mouse mammary tumor, LM05-Mix, composed of both an epithelial and a fibroblastic component. From it the respective epithelial LM05-E and fibroblastic LM05-F cell lines were generated by limiting dilution. Immunofluorescence studies confirmed that the epithelial cells were positive for E-cadherin, cytokeratins and vimentin whereas the fibroblastic cells were negative for the epithelial markers and positive for alpha-smooth muscle actin and vimentin. Both cell types expressed estrogen and progesterone receptors, although only the epithelial LM05-E cells were stimulated by estradiol and inhibited by tamoxifen. In the bicellular LM05-Mix cell line estradiol proved to stimulate cell proliferation whereas the response to tamoxifen was dependent on confluency and the degree of epithelial-fibroblastic interactions. The presence of membrane estrogen receptors in both cell types was suggested by the achievement of non-genomic responses to short treatments with estradiol, leading to the phosphorylation of ERK1/2. Finally, cytogenetic studies suggest that these two cell types represent independent cell populations within the tumor and would not be the result of an epithelial-mesenchymal transition. This model presents itself as a valuable alternative for the study of estrogen responsiveness and tamoxifen resistance in the context of epithelial-stromal interactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622696     DOI: 10.1007/s10549-008-0113-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.

Authors:  Osvaldo Pontiggia; Rocio Sampayo; Diego Raffo; Andrea Motter; Ren Xu; Mina J Bissell; Elisa Bal de Kier Joffé; Marina Simian
Journal:  Breast Cancer Res Treat       Date:  2011-09-21       Impact factor: 4.872

2.  Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.

Authors:  Ubaldo E Martinez-Outschoorn; Allison Goldberg; Zhao Lin; Ying-Hui Ko; Neal Flomenberg; Chenguang Wang; Stephanos Pavlides; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

Review 3.  Mechanisms of endocrine resistance in breast cancer.

Authors:  C Kent Osborne; Rachel Schiff
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

4.  Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

Authors:  Maria Laura Polo; Maria Victoria Arnoni; Marina Riggio; Victoria Wargon; Claudia Lanari; Virginia Novaro
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

5.  Microenvironment and endocrine resistance in breast cancer: Friend or foe?

Authors:  Sol Recouvreux; Rocío Sampayo; María Inés Díaz Bessone; Marina Simian
Journal:  World J Clin Oncol       Date:  2015-12-10

6.  Laminin Modulates the Stem Cell Population in LM05-E Murine Breast Cancer Cells through the Activation of the MAPK/ERK Pathway.

Authors:  Damián E Berardi; Diego Raffo; Laura B Todaro; Marina Simian
Journal:  Cancer Res Treat       Date:  2016-12-06       Impact factor: 4.679

Review 7.  Epigenetic factors in breast cancer therapy.

Authors:  Runjhun Mathur; Niraj Kumar Jha; Gaurav Saini; Saurabh Kumar Jha; Sheo Prasad Shukla; Zita Filipejová; Kavindra Kumar Kesari; Danish Iqbal; Parma Nand; Vijay Jagdish Upadhye; Abhimanyu Kumar Jha; Shubhadeep Roychoudhury; Petr Slama
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

8.  FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells.

Authors:  Lukasz Turczyk; Kamila Kitowska; Magdalena Mieszkowska; Kamil Mieczkowski; Dominika Czaplinska; Dominika Piasecka; Radzisław Kordek; Andrzej C Skladanowski; Piotr Potemski; Hanna M Romanska; Rafal Sadej
Journal:  Neoplasia       Date:  2017-09-01       Impact factor: 5.715

9.  Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.

Authors:  Sara Kangaspeska; Susanne Hultsch; Alok Jaiswal; Henrik Edgren; John-Patrick Mpindi; Samuli Eldfors; Oscar Brück; Tero Aittokallio; Olli Kallioniemi
Journal:  BMC Cancer       Date:  2016-07-04       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.